Heisenberg-Professur für Molekulare Mechanismen der Organfibrose

Adresse:
Krankenhausstraße 12
91054 Erlangen


Publikationen (Download BibTeX)

Go to first page Go to previous page 1 von 9 Go to next page Go to last page

De Stefano, L., Castaneda, S., De Langhe, E., Distler, J., Knitza, J., Cavazzana, I.,... Cavagna, L. (2019). RELATIONSHIP BETWEEN ANTI-MDA5 ANTIBODIES AND CANCER: RETROSPECTIVE ANALYSIS OF AN INTERNATIONAL AND MULTIDISCIPLINARY COHORT. In ANNALS OF THE RHEUMATIC DISEASES (pp. 1212-1212). Madrid, ES: LONDON: BMJ PUBLISHING GROUP.
Renoux, F., Stellato, M., Vogetseder, A., Huang, R., Subramaniam, A., Blyszczuk, P.,... Distler, O. (2019). FOSL-2 IS A REPRESSOR OF FOXP3 EXPRESSION DURING TREG DEVELOPMENT AND CONTROLS AUTOIMMUNITY. In ANNALS OF THE RHEUMATIC DISEASES (pp. 1065-1065). Madrid, ES: LONDON: BMJ PUBLISHING GROUP.
Wohlfahrt, T., Rauber, S., Luber, M., Soare, A., Weber, S., Matei, A.-E.,... Ramming, A. (2019). PU.1 INHIBITOR DB1976 CONTROLS FIBROBLAST POLARIZATION IN SYSTEMIC SCLEROSISAND LEADS TO REGRESSION OF FIBROSIS IN DIFFERENT MODELS OF ORGAN FIBROSIS. In ANNALS OF THE RHEUMATIC DISEASES (pp. 453-453). Madrid, ES: LONDON: BMJ PUBLISHING GROUP.
Pachera, E., Assassi, S., Salazar, G., Frank-Bertoncelj, M., Distler, J., Kania, G., & Distler, O. (2019). PROFIBROTIC LNCRNA H19X: UNRAVELLING THE EFFECTS ON CHROMATIN REMODELING IN SYSTEMIC SCLEROSIS FIBROBLASTS. In ANNALS OF THE RHEUMATIC DISEASES (pp. 167-168). Madrid, ES: LONDON: BMJ PUBLISHING GROUP.
Distler, J. (2019). POTENTIAL CELLULAR AND MOLECULAR TARGETS. In ANNALS OF THE RHEUMATIC DISEASES (pp. 32-33). Madrid, ES: LONDON: BMJ PUBLISHING GROUP.
Henderson, J., Distler, J., & O'Reilly, S. (2019). The Role of Epigenetic Modifications in Systemic Sclerosis: A Druggable Target. Trends in Molecular Medicine, 25(5), 395-411. https://dx.doi.org/10.1016/j.molmed.2019.02.001
Wu, W., Jordan, S., Graf, N., Pena, J.D.O., Curram, J., Allanore, Y.,... Puttini, P.S. (2019). Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Annals of the Rheumatic Diseases, 78(5), 648-656. https://dx.doi.org/10.1136/annrheumdis-2018-213455
Heim, C., Mauer, J., Kuckhahn, A., Distler, J., Spriewald, B., Ramsperger-Gleixner, M.,... Ensminger, S.M. (2019). Receptor Tyrosine Kinase Inhibitor Nintedanib as Treatment Option in Bronchiolitis Obliterans after Airway Transplantation. In JOURNAL OF HEART AND LUNG TRANSPLANTATION (pp. S139-S139). Orlando, FL, US: NEW YORK: ELSEVIER SCIENCE INC.
Wollin, L., Distler, J., Redente, E., Riches, D., Stowasser, S., & Schlenker-Herceg, R. (2019). FROM BENCH TO BEDSIDE: NINTEDANIB FOR PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES. In RESPIROLOGY (pp. 171-171). HOBOKEN: WILEY.
Harrach, S., Barz, V., Pap, T., Pavenstaedt, H., Schlatter, E., Edemir, B.,... Bertrand, J. (2019). Notch Signaling Activity Determines Uptake and Biological Effect of Imatinib in Systemic Sclerosis Dermal Fibroblasts. Journal of Investigative Dermatology, 139(2), 439-447. https://dx.doi.org/10.1016/j.jid.2018.08.021
Kreuter, M., Bonella, F., Blank, N., Siegert, E., Henes, J., Worm, M.,... Hunzelmann, N. (2019). Predictors for the Development of Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) - Data from the German SSc-Network. In AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. Dallas, TX, US: NEW YORK: AMER THORACIC SOC.
Wohlfahrt, T., Rauber, S., Uebe, S., Luber, M., Soare, A., Ekici, A.B.,... Ramming, A. (2019). PU.1 controls fibroblast polarization and tissue fibrosis. Nature. https://dx.doi.org/10.1038/s41586-019-0896-x
Knitza, J., Cavagna, L., Schett, G., & Distler, J. (2019). Response to: 'Idiopathic inflammatory myopathies and antisynthetase syndrome: Contribution of antisynthetase antibodies to improve current classification criteria' by Greco et al. Annals of the Rheumatic Diseases. https://dx.doi.org/10.1136/annrheumdis-2019-215484
Elhai, M., Boubaya, M., Distler, O., Smith, V., Matucci-Cerinic, M., Alegre Sancho, J.J.,... Allanore, Y. (2019). Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: A prospective cohort study. Annals of the Rheumatic Diseases. https://dx.doi.org/10.1136/annrheumdis-2018-214816
Wollin, L., Distler, J., Denton, C.P., & Gahlemann, M. (2019). Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis–associated interstitial lung disease. Journal of Scleroderma and Related Disorders. https://dx.doi.org/10.1177/2397198319841842
Liang, R.f., Kagwiria, R., Zehender, A., Dees, C., Bergmann, C., Ramming, A.,... Distler, J. (2019). Acyltransferase skinny hedgehog regulates TGFβ-dependent fibroblast activation in SSc. Annals of the Rheumatic Diseases. https://dx.doi.org/10.1136/annrheumdis-2019-215066
Zehender, A., Huang, J., Gyoerfi, A.-H., Matei, A.-E., Thuong Trinh-Minh, ., Xu, X.,... Distler, J. (2018). The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis. Nature Communications, 9(1). https://dx.doi.org/10.1038/s41467-018-05768-3
Gocht, A., Distler, J., Spriewald, B., Ramsperger-Gleixner, M., Ensminger, S.M., Weyand, M., & Heim, C. (2018). Blockade of Tyrosine Kinases as Preventive Strategy Against Cardiac Allograft Vasculopathy in a Murine Aortic Transplant Model. (pp. S452-S452).
Soare, A.M., Gyoerfy, H., Matei, A.-E., Dees, C., Zhang, Y., Wohlfahrt, T.,... Distler, J. (2018). DIPEPTIDYL-PEPTIDASE-4 (DPP4) IS A POTENTIAL NEW MOLECULAR TARGET FOR TREATMENT OF FIBROSIS. (pp. 735-736).
Pötter, S., Dees, C., Bergmann, C., Ramming, A., Distler, O., Schett, G., & Distler, J. (2018). Inhibition of Nuclear Receptor Coactivator 3 Attenuates Fibrosis in Murine Models of Systemic Sclerosis.

Zuletzt aktualisiert 2019-24-04 um 10:31